merged_eli-lilly-zepbound-price.txt
<other>Let me analyze each question based solely on the article provided.</other>

<question_number>1</question_number>
<answer>Lilly is positioning its vials as a safer option than compounded drugs, which are subject to far less oversight than traditionally approved medications</answer>

<question_number>2</question_number>
<answer>Like compounded drugs prescribed by online startups, Zepbound vials can be delivered right to patients' doors through LillyDirect</answer>

<question_number>3</question_number>
<answer>Compounded drugs are subject to far less oversight than traditionally approved medications, and health officials have repeatedly warned against taking compounded weight-loss drugs</answer>

<question_number>4</question_number>
<answer>"Maybe this is a signal to that space: 'We will get this market share back from you, even if it means lower pricing'"</answer>

<question_number>5</question_number>
<answer>Compounding pharmacies can make copycat versions of any medication the FDA lists as "in shortage," and when tirzepatide is off the shortage list, "there should be no space for mass compounders"</answer>

<question_number>6</question_number>
<answer>N/A</answer>

<question_number>7</question_number>
<answer>Drugs come with unique risks for older patients, including a loss of muscle mass that may make people over 65 more likely to suffer fractures or become frail</answer>

<question_number>8</question_number>
<answer>Lilly is positioning its vials as a safer option than compounded drugs for people who cannot afford its pens</answer>

<question_number>9</question_number>
<answer>Being listed as "in shortage" by the FDA</answer>

<question_number>10</question_number>
<answer>Lower pricing</answer>